A long-term study of symptoms, spirometry and survival amongst home nebulizer users  by O'Driscoll, B.R. & Bernstein, A.
Respiratory Medicine (1996) 90, 561-566 
A long-term study of symptoms, spirometry and 
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B. R. O’DRISCOLL* AND A. BERNSTEIN 
Salford Royal Hospitals NHS Trust, Hope Hospital, SaFford, U.K. 
Although home nebulizers are widely used to deliver bronchodilator medication to patients with asthma and 
chronic obstructive pulmonary disease (COPD), the long-term benefits and hazards are unknown. 
The present authors have previously reported a prospective 12-month study of home nebulizer use involving 
49 patients (15 asthma, mean forced expiratory volume in 1 s/forced vital capacity (FEV,/FVC) 1.3/2.1 1; 
34 COPD, mean FEVJFVC 0.7/1.8 1). Thirty-two of these patients were treated with long-term domiciliary 
nebulized bronchodilator treatment, the other 17 patients chose metered dose inhaler (MDI) therapy. The 
present paper reports the progress of these patients over 5 yr. 
Five-year survival was similar in both groups (nebulizer users 56%, MD1 users 53%). Most deaths were due 
to respiratory failure (14 deaths) or lung cancer (four deaths). Survival was determined mainly by FEV, 
(R=0.54, P=O.OOOl) and age (R= - 0.47, P=O.O007). 
Laboratory lung function tests (16 nebulizer users) showed that FEV, and FVC were still higher than 
pre-nebulizer baseline measurements after 36 months of nebulizer use, but PEFR had fallen by 7%. 
Twenty-one of 23 surviving nebulizer users completed a questionnaire after 36 months of treatment. All 
used their nebulizer at least once per day and 20 of 21 patients reported that they still obtained full benefit 
from each nebulized treatment. The morning peak flow response to nebulized treatment was the same at 
baseline and at 36 months (48 1 min - ‘). 
All patients remained breathless (mean subjective score 4.8 on seven-point scale) but the subjective response 
to nebulized treatment was unchanged at 36 months. 
Tachyphylaxis did not develop among 13 patients who underwent repeated reversibility studies using 2OOpg 
of salbutamol at 6, 12 and 36 months. 
It is concluded that home nebulizer therapy is safe and effective for a small number of carefully selected 
patients with severe asthma or COPD, who have been evaluated by a rigorous home nebulizer assessment 
protocol prior to commencing home nebulizer therapy. 
Introduction 
Many thousands of patients with severe asthma 
and chronic obstructive pulmonary disease (COPD) 
are treated by bronchodilator drugs administered via 
a nebulizer device. In the past, such devices were used 
by patients who had difficulty using conventional 
metered dose inhaler (MDI) devices, but most such 
patients can now be treated using large volume 
spacers, breath-activated inhalers or dry powder 
devices. There remain a small number of patients 
who appear to require very high doses of P-agonist or 
anticholinergic treatment and such treatment can be 
given most effectively using a hand-held small volume 
nebulizer. 
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It has been suggested that, in many cases, the 
response to nebulized treatment may be a placebo 
effect (l), and some, but not all, previous studies of 
home nebulizer use have demonstrated subjective 
and objective benefit superior to that obtained from 
conventional MD1 devices (14). 
Most such studies were of short duration (2-8 
weeks). Two retrospective studies of home nebulizer 
use in uncontrolled settings over 2-5 yr have shown 
subjective benefit, and one of these studies reported 
a non-significant reduction in hospital admissions 
amongst home nebulizer users (5,6). The effect of 
home nebulizers on mortality is not yet known but it 
has been suggested that high-dose P-agonist treat- 
ment might increase mortality (7). However, a retro- 
spective survey failed to demonstrate any evidence of 
drug toxicity in a study of mortality amongst home 
nebulizer users (8). 
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Table I Clinical details of patients at entry to study 
Asthma COPD 
Number of patients 
Number of smokers 
Mean age, years (range) 
Mean PEF, 1 min- ' (SD) 
Mean PEF post salbutamol 
Mean FEV, 1 (SD) 
Mean FVC, (SD) 
Mean KC0 as percent of 
predicted value (range) 
Inhaled steroid 
Number of users 
Mean daily dose 
Oral prednisolone 
Number of users 
Mean daily dose 
15 (6M, 9F) 
1 current, 10 ex 
54 (43-74) 
194 (118) 
231 (20% rise) 
1.31 (0.8) 
2.11 (1.1) 
105% (83-128) 
15 
1681 ,ug 
8 
8mg 
34 (21M, 13F) 
11 current, 22 ex 
61 (35-75) 
157 (66) 
171 (11% rise) 
0.71 (0.3) 
1.81 (0.8) 
62% (222110) 
23 
1565yg 
11 
8mg 
Oral theophylline 
Number of users 
Mean daily dose 
Oral b-agonist 
Number of users 
Mean daily dose 
9 21 
594 mg 702 mg 
1 5 
12mg 10.6 mg 
COPD, chronic obstructive pulmonary disease; PEF, peak expiratory flow; FEV,, forced 
expiratory volume in 1 s; KCO, carbon monoxide transfer; *PEF was measured before and 
15 min after 200 pg salbutamol from metered dose inhaler. 
The present authors have previously reported a 
prospective assessment of 49 patients who were 
referred for consideration of home nebulizer use (2). 
Thirty-two of these patients commenced long-term 
domiciliary nebulized treatment and 17 patients con- 
tinued to use MD1 treatment. It was reported that the 
nebulizer users had subjective and objective improve- 
ment (compared with their previous therapy) during 
1 yr of home nebulizer use. These patients have been 
observed over a 3-yr period and the present paper 
reports the spirometry, reversibility tests and subjec- 
tive symptoms during this period together with 
mortality data over a 5-yr period. 
Patients and Methods 
The clinical features, spirometry and initial drug 
treatment of these patients are given in Table 1, and 
full details of their initial home nebulizer assessment 
have been published previously in Respiratory Medi- 
cine (2). Of 49 patients assessed, 15 had asthma 
(mean FEV,/FVC 1.312.1) and 34 patients had 
COPD [mean forced expiratory volume in 1 s/forced 
vital capacity (FEV,/FVC) 0.7H.81. Two-thirds of 
each group (lo/15 asthma; 22/34 COPD) requested 
long-term home nebulizer treatment. The choice of 
nebulizer therapy or MD1 therapy was made by each 
patient on the basis of their response during a 
4-month assessment period. Most MD1 users were 
given moderately high doses of bronchodilator (1 mg 
terbutaline and 8Opg ipratropium bromide) four 
times daily via a large volume spacer device 
(Nebuhaler, Astra U.K. Ltd). Of the 32 home 
nebulizer users, nine used nebulized salbutamol 
(5 mg), five used nebulized ipratropium bromide 
(0.5 mg) and 18 used a mixture of both drugs. All 
patients administered the nebulized treatment four 
times daily at first, but both the medication and the 
dosage changed slightly over 5 yr as reported below. 
The 32 nebulizer users and the 17 MD1 users had 
similar spirometry at entry to the study (nebulizer 
users FEV,/FVC 0.82/1.79; MD1 users FEV,/FVC 
0.92/2.13; non-parametric ANOVA BO.05, n.s.). 
The mean age was also similar (nebulizer users 
58 years, MD1 users 58 years). 
All patients had laboratory lung function tests and 
reversibility testing using 200 pg of salbutamol from 
a MD1 prior to entering the study. Patients omitted 
all bronchodilator treatment for 8 h prior to revers- 
ibility testing. All surviving home nebulizer users 
were invited to attend for further laboratory lung 
function tests and reversibility tests 36 months 
after entering the study, and they were also asked 
to complete a questionnaire which asked about 
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nebulizer use, other medical treatment and subjective 
assessments of breathlessness. 
The patients’ sense of wellbeing was assessed using 
a 10 cm visual analogue scale (O=perfectly well; 
lO=extremely unwell). All patients had kept peak 
flow diaries before entering the study and during the 
first 3 months of home nebulizer use. All nebulizer 
users were asked to repeat these diaries after 36 
months of home nebulizer use. These assessments 
were not repeated at 60 months as the number of 
survivors in each group was too small to make any 
meaningful comparisons. 
Home peak flow measurements were made using 
a Wright’s mini peak flow meter (Clement Clark 
International). Spirometry was performed using a dry 
bellows spirometer (Vitalograph, U.K.). Details of 
the nebulizer systems and compressors which were 
used are given in the Results section of this paper. 
Deaths amongst this group of patients were ident- 
ified from hospital activity data and by contacting the 
family practitioner of each patient at intervals. Apart 
from the patients who died, only one patient left the 
district and was lost to long-term follow-up. Surviv- 
ing patients were contacted by a respiratory nurse 
and asked to complete questionnaires, peak flow 
diaries and laboratory lung function tests 36 months 
after entering the study. All 49 patients had full 
clinical and laboratory assessment prior to entering 
the study. Of 32 nebulizer users, 23 were alive at 36 
months. Twenty-one of these survivors completed a 
follow-up questionnaire and 16 were willing and able 
to attend the hospital for further lung function tests 
and reversibility studies. Four patients said that 
they were unable to attend for reversibility tests 
because they could not withhold their early morning 
nebulized bronchodilator treatment. 
Two MD1 users converted to nebulized treatment 
during the 5 yr follow-up and two nebulizer users 
reverted to MD1 use. A further two nebulizer users 
were only using their nebulizer intermittently at the 
time of the 5-yr assessment. For purposes of mor- 
tality studies, each patient was assessed according to 
the actual treatment which they were using at the 
time of death. Some patients also changed their 
nebulized medication or the dose or frequency of 
administration during the follow-up period. Details 
of treatment at the 36-month assessment are given 
in the Results section of this paper. This study was 
approved by the Hospital Ethics Committee. 
Results 
SURVIVAL 
Five-year survival was similar amongst nebulizer 
users (56%) and MD1 users (53%). The survival 
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Fig. I Survival of nebulizer users (---, n=32) and 
metered dose inhaler users (- - -, n = 17) over a 5-yr period. 
Survival curve analysis P=O-77, n.s. 
Table 2 Causes of death 
Nebulizer users MD1 users 
n=32 n=17 
Respiratory failure 
Lung cancer 
Myocardial infarction 
Cor pulmonale 
Total deaths 
7 (22%) 7 (41%) 
4 (12%) 
2 (6%) 1 (6%) 
1 (3%) 
14 (44%) 8 (47%) 
MDI, metered dose inhaler. 
curves for both groups are shown in Fig. 1. Most 
deaths (64%) were due to respiratory failure with 
only 6% in each group dying of myocardial infarction 
(Table 2). Nineteen of 22 deaths occurred in COPD 
patients. Three asthmatic patients died; two died of 
respiratory failure (both aged 76 years, both using 
MDI, FEV, 0.75 and 0.70 1) and one died of lung 
cancer (current smoker of 20 cigarettes day- ‘). 
Survival was predicted by initial FEV, (Spearman 
correlation coefficient R=0.54; 95% CI 0.30-0.72; 
P=O.OOOl). The 27 long-term survivors had an initial 
mean FEV, of 1.1 1; the 22 patients who died during 
5 yr of observation had an initial mean FEV, of 
only 0.59 1 (P<O.OOl). Survival was inversely related 
to age at entry to the study (Spearman correlation 
coefficient R= - 0.47; 95% CI - 0.66- - 0.20; 
P=O.O007). 
SPIROMETRY 
Figure 2 shows the changes which occurred in 
laboratory measurements of PEFR, FEV, and FVC 
during 36 months of home nebulizer use. The average 
PEFR was above baseline after 6 months of home 
nebulizer use, level with baseline at 12 months and 
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6 months 12 months 36 months 
Fig. 2 Laboratory lung function data during 36 months 
of home nebulizer use (16 patients). Baseline values for 
these patients: mean peak expiratory flow rate (PEFR), 
176 1 min r; mean forced expiratory volume in 1 s (FEV,), 
0.87 1; mean forced vital capacity (FVC), 1.92 1. Stippled 
bars, PEFR; solid bars, FEV,; hatched bars, FVC. 
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Fig. 3 Mean peak expiratory flow rate (PEFR) [morning 
pre-treatment (stippled bars) and 30 min post-treatment 
(solid bars) averaged over 28 days] before home nebulizer 
assessment, during first month, and during 36th month of 
treatment (21 patients). MDI, metered dose inhaler. 
slightly (7%) below baseline at 36 months. The FEV, 
and FVC remained above baseline at 36 months. 
DOMICILIARY PEAK FLOW CHARTS 
Twenty-one nebulizer users kept a peak flow diary 
card for 4 weeks after approximately 36 months of 
therapy. Their mean morning PEFR before and after 
treatment is shown in Fig. 3. The morning PEFR at 
36 months was similar to the baseline PEFR but not 
as high as their PEFR during the initial months of 
home nebulizer therapy. However, the fall in pre- 
nebulizer morning PEFR between 1987-88 and 
1990-91 (from 196 to 172 1 min- ‘) amounts to a fall 
ofSlyr-’ which might be expected with advancing 
age. The patients’ response to the morning dose of 
nebulized bronchodilator treatment was the same at 
36 months (48 1 mini ’ or 28%) as it was when 
nebulized treatment was first given (48 1 min- i or 
24%). 
REVERSIBILITY TO LOW-DOSE SALBUTAMOL 
Thirteen patients had technically satisfactory 
reversibility tests using 200 pug salbutamol at baseline 
and after 36 months of home nebulizer use. The 
baseline data and reversibility results are shown in 
Table 3; there was no diminution in the response to 
low-dose salbutamol after 36 months of high-dose 
nebulized salbutamol therapy (average dose 21 mg 
day - I). 
CHOICE OF TREATMENT 
Two patients changed from MD1 use to nebulizer 
use during the 5 yr of follow-up, and two changed 
from nebulizer to MD1 treatment. As time passed, 
patients or doctors tended to intensify nebulized 
treatment. Of 21 nebulizer users who completed a 
diary at 36 months, 17 were taking both salbutamol 
and ipratropium in their nebulizer, four were using 
salbutamol alone and no patient was still using 
ipratropium bromide alone. Most patients (16) were 
using the nebulizer four times daily, with one patient 
using it three times daily and four patients using the 
device five or six times per day (frequency of use was 
at the patients’ discretion). 
SIDE-EFFECTS 
Patients did not acquire tolerance to the side- 
effects of high-dose P-agonist treatment. Eleven 
patients (52%) had one or more side-effects at 36 
months (10 tremor, four palpitations, one headache). 
However, these side-effects were minor compared 
with the degree of breathlessness suffered by these 
patients (Fig. 4). 
RELIABILITY OF EQUIPMENT 
No patients reported difficulty using their nebulizer 
equipment. Eighteen patients used ‘Porta-Neb’ com- 
pressors with ‘System 22’ nebulizers (Medic Aid, 
U.K.) and three used ‘Medix’ compressors with ‘Bard 
Inspiron’ nebulizer chambers. There were only three 
mechanical breakdowns during 3 yr of daily use; 18 
compressors developed no mechanical faults during 
this time. 
SUBJECTIVE RESPONSES AND QUALITY OF LIFE 
Of the 21 patients who completed a questionnaire 
after 36 months of home nebulizer use, 20 reported 
that they derived as much benefit from their 
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Table 3 Response to low-dose salbutamol during 36 months of home nebulizer use 
Baseline 6 months 12 months 36 months 
PEF 179 179 167 165 
Mean % rise after 200 ,~g salbutamol 14.6 15.2 157 13.0 
Number of patients 13 11 11 13 
PEF, peak expiratory flow (1 min - I). Mean peak flow was measured in the laboratory before 
and 15 min after inhaling 200 pg salbutamol from metered dose inhaler. 
nebulized bronchodilator treatment in 1990-91 as 
they had in 1987-88. This is consistent with the 
unaltered PEFR response described above. One 
patient reported that the nebulized treatment gave 
him less relief in 1990 than he had obtained in 1987. 
All patients reported that their mobility was 
restricted by breathlessness but none of them 
described themselves as ‘house-bound’. The average 
score for wellbeing on a 10 cm visual analogue scale 
(O=perfectly well; lO=extremely unwell) was 4.6 
(range 2.2-7.3; SD 1.5). 
Discussion 
Although this study is prospective, it is not a 
randomized study so the comparisons between the 
(self-selected) home nebulizer group and the MD1 
group must be interpreted with some caution. How- 
ever, the patients in this study were assessed and 
treated in accordance with the new U.K. Guidelines 
for home nebulizer assessment (9), so the observa- 
tional data which was gathered over 5 yr will be 
representative of what might be expected in clinical 
practice in the U.K. 
The most important data from the present study 
relates to patient safety and continuing subjective 
and objective benefit during 5 yr of treatment. 
SOB T P NSOB ROA 
Fig. 4 Symptom scores during 36 months of nebulizer use. 
SOB, shortness of breath; T, tremor; P, palpitations; NSOB, 
nocturnal SOB; ROA, restriction of activity. Baseline, using 
metered dose inhaler before nebulizer trial (solid bars); first 
month of home nebulizer use (hatched bars), 36th month 
(stippled bars). 
Although the number of patients is too small to 
exclude a modest effect of nebulizer use on mortality 
(either adverse or beneficial), the survival curves of 
nebulizer users and MD1 users were almost identical 
and patients in this study died of expected causes 
(respiratory failure, lung cancer and ischaemic heart 
disease). There was no excess of arrhythmic or unex- 
plained deaths in the home nebulizer group. Mor- 
tality was related to age and lung function as has 
been reported previously for patients with obstructive 
lung disease (10). This would support previous sug- 
gestions that the slight excess mortality which has 
been recorded among home nebulizer users is due to 
disease severity rather than due to treatment-related 
deaths (11). Most of the patients who died in the 
present study had very poor lung function at entry to 
the study, and would not have been expected to 
survive for a further 5 yr. 
This study confirms previous observations that, 
although tachyphylaxis (reduced responsiveness to 
P-agonist treatment following repeated doses) can be 
demonstrated in laboratory studies, it is not a major 
issue in the long-term treatment of patients with 
severe airflow obstruction (12,13). The objective 
response to 200,~~g of salbutamol and the subjective 
and objective response to 5 mg of nebulized salbuta- 
mol were unaltered during 3 yr of home nebulizer 
therapy using 20-30 mg salbutamol day ~ i. 
It has been suggested that regular P-agonist treat- 
ment may cause an accelerated decline in FEV, or 
PEFR in asthmatic and COPD patients (7,14,15). 
The patients in the present study experienced an 
initial rise in FEV, and PEFR on commencement 
of home nebulized therapy and declined towards 
baseline levels during 3 yr of follow-up. However, 
the FEV, of these patients remained above the 
pre-nebulizer level after 3 yr of high-dose treatment 
and the rate of decline of FEV, over 3 yr (from the 
patients maximum level during their first month of 
nebulized treatment) was only 16 ml yr ~ I, whereas 
the expected rate of decline in patients with 
severe airllow obstruction is about 50-70 ml yr ~ i 
(16-18). 
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The 5-yr mortality of about 50% is very similar to 
that reported previously for this category of patients 
(17). 
Some physicians have suggested that nebulized 
bronchodilator treatment has a large placebo effect 
(1). Whereas this may be true in short-term trials, one 
would expect a placebo effect to have worn off after a 
few months, but the authors found that 95% of the 
study patients reported no attenuation of benefit 
during 3 yr of home, nebulizer use. Furthermore, 
the peak flow response to high-dose nebulized bron- 
chodilator at 36 months (28%) remained greater than 
the peak flow response to low-dose salbutamol treat- 
ment (13%) or medium-dose MD1 treatment (23%). 
This dose-response relationship provides a biologi- 
cally plausible explanation for the patients subjective 
preference for high-dose nebulized treatment. 
The quality-of-life measurements demonstrated 
that these patients had adapted to their chronic 
disease state. Although all were breathless, none were 
housebound and they reported their sense of well- 
being as closer to ‘perfectly well’ than ‘extremely 
unwell’. 
This study shows that patients who have been 
evaluated carefully prior to home nebulizer therapy 
will continue to derive subjective and objective ben- 
efit from high-dose bronchodilator therapy over a 
3-yr period. Mortality in this group is mainly related 
to age and FEV,. 
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